Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a pharmaceutical giant with a market capitalization of $735 billion and an "GREAT" financial health rating according to InvestingPro, announced ...

Bernstein SocGen Group reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY) stock Monday, citing continued strong performance of its weight loss medication Zepbound ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...